Export 122 results:
Filters: First Letter Of Last Name is W  [Clear All Filters]
I
Coster, T. S., Wolf M. K., Hall E. R., Cassels F. J., Taylor D. N., Liu C. T., et al. (2007).  Immune response, ciprofloxacin activity, and gender differences after human experimental challenge by two strains of enterotoxigenic Escherichia coli. Infection and immunity. 75, 1.
Havelaar, A. H., van Pelt W., C Ang W., Wagenaar J. A., van Putten J. P. M., Gross U., et al. (2009).  Immunity to Campylobacter: its role in risk assessment and epidemiology. Critical reviews in microbiology. 35, 1–22.
Havelaar, A.. H., Pelt W.., Ang C.. W., Wagenaar J.. A., Putten J.. P., Gross U.., et al. (2009).  Immunity to ''Campylobacter'': its role in risk assessment and epidemiology. Critical Reviews in Microbiology. 1-22.
Taylor, D. M., Woodgate S. L., & Atkinson M. J. (1995).  Inactivation of the bovine spongiform encephalopathy agent by rendering procedures. Veterinary Record. 137(24), 
Ward, R.., Krugman S.., Giles J.. P., Jacobs A.. M., & Bodansky O.. (1958).  Infectious hepatitis; studies of its natural history and prevention. The New England journal of medicine. 258, 9.
Okhuysen, P. C., Rich S. M., Chappell C. L., Grimes K. A., Widmer G., Feng X., et al. (2002).  Infectivity of a Cryptosporidium parvum Isolate of Cervine Origin for Healthy Adults and Interferon-γ Knockout Mice. Journal of Infectious Diseases. 185, 9.
Chappell, C. L., Okhuysen P. C., Sterling C. R., Wang C., Jakubowski W., & Dupont H. L. (1999).  Infectivity of Cryptosporidium parvum in healthy adults with pre-existing anti-C. parvum serum immunoglobulin G.. The American journal of tropical medicine and hygiene. 60, 157–164.
Bravata, D. M., Holty J-E. C., Wang E., Lewis R., Wise P. H., McDonald K. M., et al. (2007).  Inhalational, gastrointestinal, and cutaneous anthrax in children: a systematic review of cases: 1900 to 2005. Archives of pediatrics & adolescent medicine. 161, 896–905.
Bravata, D. M., Holty J-E. C., Wang E., Lewis R., Wise P. H., McDonald K. M., et al. (2007).  Inhalational, gastrointestinal, and cutaneous anthrax in children: a systematic review of cases: 1900 to 2005. Archives of pediatrics & adolescent medicine. 161, 896–905.
Bravata, D.., Holty J.., Wang E.., Lewis R.., Wise P.., Mcdonald K.., et al. (2007).  Inhalational, Gastrointestinal, and Cutaneous Anthrax in Children. Arch Pediatr Adolesc Med. 896-905.
Bravata, D.., Holty J.., Wang E.., Lewis R.., Wise P.., Mcdonald K.., et al. (2007).  Inhalational, Gastrointestinal, and Cutaneous Anthrax in Children. Arch Pediatr Adolesc Med. 896-905.
M
Guidi-Rontani, C.., M. Weber-Levy L., & E. M. (1999).  M. Germination of ''Bacillus anthracis'' Spores Within Alveolar Macrophages. Molecular Microbiology. 31, 9-17.
Henrickson, S. E., Wong T., Allen P., Ford T., & Epstein P. R. (2001).  Marine swimming-related illness: implications for monitoring and environmental policy.. Environmental Health Perspectives. 109, 645–650.
Horney, L.. F., & Walker D.. H. (1988).  Meningoencephalitis as a major manifestation of Rocky Mountain spotted fever. 915-918.
South Med. J. 81
Weir, M. H., & Haas C. N. (2011).  A model for in-vivo delivered dose estimation for inhaled Bacillus anthracis spores in humans with interspecies extrapolation. Environmental science & technology. 45, 5828–5833.
Weir, M.. H., & Haas C.. N. (2011).  A Model for In-vivo Delivered Dose Estimation for Inhaled ''Bacillus anthracis'' Spores in Humans with Interspecies Extrapolations. Environmental Science and Technology. 45, 5828-5833.
Kotloff, K. L., Nataro J. P., Losonsky G. A., Wasserman S. S., Hale T. L., Taylor D. N., et al. (1995).  A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine. 13, 1488–1494.
Albuquerque, N. D., Baig E., Ma X., Zhang J., He W., Rowe A., et al. (2006).  Murine Hepatitis Virus Strain 1 Produces a Clinically Relevant Model of Severe Acute Respiratory Syndrome in A/J Mice. Journal of Virology. 80, 21.